DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021762/S-005, S-009, S-010 **SUPPLEMENT APPROVAL**

Merck & Co., Inc.
Attention: James Adams
Associate Director, Worldwide Regulatory
126 E. Lincoln Avenue
P.O. Box 2000
Mail Drop: RY33-200
Rahway, NJ 07065-0900

Dear Mr. Adams:

Please refer to the following supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for FOSAMAX PLUS D (alendronate sodium/cholecalciferol) tablets:

Supplement Number	Letter Date	Date Received
S-005	July 9, 2007	July 9, 2007
S-009	June 10, 2009	June 10, 2009
S-010	July 2, 2009	July 2, 2009

We also acknowledge receipt of the following submissions:

Supplement Number	Letter Date	Date Received
S-005	June 25, 2009	June 25, 2009
S-005	January 13, 2010	January 13, 2010
S-009	June 23, 2009	June 23, 2009
S-009	January 13, 2010	January 13, 2010
S-010	July 31, 2009	July 31, 2009
S-010	January 13, 2010	January 13, 2010

For Supplement 005, your submission of June 25, 2009, constituted a complete response to our April 3, 2008, action letter.

These supplemental new drug applications provide for the following labeling changes:

Supplement 005

- Revision of Section 5.4, Osteonecrosis of the Jaw, of the FULL PRESCRIBING INFORMATION and the Post-Marketing Experience subsection in the ADVERSE REACTIONS section of the FULL PRESCRIBING INFORMATION that relates to osteonecrosis of the jaw.
- Revision of Patient Labeling (section entitled "What should I tell my doctor before using FOSAMAX PLUS D?") to include dental conditions.

Supplement 009

- Revision of the CONTRAINDICATIONS section of HIGHLIGHTS regarding FOSAMAX PLUS D use in patients with abnormalities of the esophagus which delay emptying so that the wording is identical to that in the CONTRAINDICATIONS section of the FULL PRESCRIBING INFORMATION.
- Minor revision of subsection 5.1, Upper Gastrointestinal Adverse Reactions, of the WARNINGS AND PRECAUTIONS section of the FULL PRESCRIBING INFORMATION regarding the use of bisphosphonates in patients with active upper gastrointestinal problems and the upper gastrointestinal adverse events associated with the use of bisphosphonates.

Supplement 010

- Revision of the Post-Marketing Experience subsection of the ADVERSE REACTIONS section of FULL PRESCRIBING INFORMATION. The revision added "low-energy femoral shaft and subtrochanteric fractures" to the *Musculoskeletal* subsection.
- Minor editorial changes in table footnotes in FULL PRESCRIBING INFORMATION.
- Revision of Patient Labeling (section entitled "What are the possible side effects of FOSAMAX PLUS D?") to inform patients about femoral fractures.

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling. For administrative purposes, please designate this submission, "SPL for approved NDAs 021762/S-005, 021762/S-009, 021762/S-010."

PROMOTIONAL MATERIALS

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to

your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the following address or by facsimile at 301-847-8444:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

In addition, as required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Karl Stiller, Regulatory Project Manager, at (301) 796-1993.

Sincerely,

{See appended electronic signature page}

Scott Monroe, M.D.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-21762	SUPPL-10	MERCK AND CO INC	FOSAMAX PLUS D TABLETS
NDA-21762	SUPPL-9	MERCK AND CO INC	FOSAMAX PLUS D TABLETS
NDA-21762	SUPPL-5	MERCK AND CO INC	FOSAMAX PLUS D TABLETS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SCOTT E MONROE
03/01/2010